Utah Medical Products Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1994
Net Income	16.64	16.47	14.79	10.8	14.73	18.56	8.51	12.13	11.84	11.38	Upgrade
Depreciation & Amortization	6.37	7.08	7.28	7.21	6.88	2.96	2.77	2.83	3.15	3.36	Upgrade
Share-Based Compensation	0.24	0.19	0.21	0.17	0.14	0.11	0.13	0.09	0.09	0.07	Upgrade
Other Operating Activities	-0.96	-2.6	-1.07	1.96	-4.69	-4.79	5.5	-0.53	-1.28	0.58	Upgrade
Operating Cash Flow	22.28	21.15	21.2	20.14	17.06	16.83	16.91	14.53	13.8	15.39	Upgrade
Operating Cash Flow Growth	5.36%	-0.26%	5.29%	18.06%	1.32%	-0.44%	16.38%	5.27%	-10.31%	25.02%	Upgrade
Capital Expenditures	-0.64	-0.81	-0.55	-0.86	-0.54	0.46	-1.6	-3.29	-0.18	-1.11	Upgrade
Change in Investments	0	0	0	0	0	0.07	0	0	0	0	Upgrade
Other Investing Activities	-	-0.01	-	-	-21	-	-	-0.01	-0.07	-0.02	Upgrade
Investing Cash Flow	-0.64	-0.82	-0.55	-0.86	-21.54	0.53	-1.6	-3.3	-0.25	-1.13	Upgrade
Dividends Paid	-4.28	-3.16	-11.47	-4.12	-4.11	-4.03	-2.96	-3.92	-3.85	-3.77	Upgrade
Share Issuance / Repurchase	0.12	-2.32	0.56	-6.62	-0.12	-0.75	0.3	-2.47	-0.34	-0.56	Upgrade
Debt Issued / Paid	0	0	0	0	0	0	0	0	-4.78	-4.04	Upgrade
Other Financing Activities	-	-	-	-	-	-	-	0.05	0.07	0.1	Upgrade
Financing Cash Flow	-4.17	-5.48	-10.91	-10.73	-4.23	-4.78	-2.65	-6.34	-8.89	-8.26	Upgrade
Exchange Rate Effect	0.34	-0.77	-0.36	0.26	0.39	-1.35	0.92	-1.87	-0.66	-1.12	Upgrade
Net Cash Flow	17.82	14.08	9.38	8.8	-8.33	11.24	13.58	3.02	4	4.88	Upgrade
Free Cash Flow	21.64	20.34	20.65	19.28	16.52	17.29	15.31	11.24	13.63	14.28	Upgrade
Free Cash Flow Growth	6.41%	-1.52%	7.13%	16.72%	-4.50%	12.95%	36.28%	-17.54%	-4.57%	19.28%	Upgrade
Free Cash Flow Margin	43.09%	38.90%	42.10%	45.70%	35.21%	41.18%	36.97%	28.59%	33.93%	34.59%	Upgrade
Free Cash Flow Per Share	5.96	5.61	5.66	5.29	4.44	4.63	4.12	2.99	3.63	3.81	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).